MAKO Surgical Corp. (NASDAQ:MAKO)

Aging baby boomers needing new knees, faster recoveries matter

back in

I believe Minimal invasive surgery will only become bigger and bigger. In the future, when the younger doctors grow with this technology it will only become more pervasive.

Bottomed out.Increasing Revenues.Massive growth potential.Not many competitors.

Well equipped to compete in a growing market (joint replacement robots) with a high barrier to entry. Main competitor is having legal problems surrounding product performance. Despite MAKO's own problems meeting shareholder expectations, revenue is increasing.

Technical: Stock was battered down to below 1/4 of its 52-week high. Has formed a triangle, with low volume on last sell off. Not a classic head and shoulders pattern; but higher lows indicate a bottom has been reached. Renko chart confirms change in trend direction.

No. The ACA tax on medical devices is going to either make this company a buyout for Intuitive Surgical or they will simply go out of business under the weight of government regulation now that Obama has got 4 more years to ruin the economy further.

The machines are working and in use. Though the projected sales are not as high as they could be, they're still going strong, which means they're not as bad as one orthopedic surgeon top bear seems to think.

MAKO is successfully crossing the technological chasm. Sales of surgical robots have rebounded as they bring onboard more "early majority" customers, and procedure rates per installed robot remain steady indicating continued strong use by both current and new surgeons.

Crazy cheap right now.

New medical instruments companies always have ups and downs, but the thing to watch is that the first loss earnings are being reduced on a steady basis as the company heads for profitability. Mako does so.

I'm going with the crowd.

A lot of money

Anyone else thinking about the sharks with laser beams here?

the growth story of mako is over. q4/2012 declines from q4/2011

probably not an ISRG but still a great opportunity cinsidering its beaten-down prize and the potential for growth for robotic knee and hip surgeries.

glad i did not buy this one in real life.

It's been beaten down and has held this level for a while. If it pops, it will go fast so best to be in already. Limited downside with lots of potential upside.

Revolutionizing the way certain key surgeries are done. At bottom of a 52-week high, I think it will outperform from this price point in the short term and outperform in long term as well.

The number of robotic arms sold increased this quarter (15 sold 3Q 2012) and it's just beginning to get traction in the medical community. Once these 'razors' are sold, the 'blades' will follow and I like the prospects, especially with the new hip application on top of the knee application. I have this in my portfolio and I am continuing to buy at these levels ($14 - $16 range). There is the possibility of the use of the robotic arm to be expanded to include shoulders, though there is nothing definite about that other than rumors. Still, I like the long term growth possibilities with this company and I'm backing it as part of my aggressive section of my portfolio.